Cost-benefit analysis of ALK diagnosis vs. non-diagnosis in patients with advanced non–small cell lung cancer in Spain
Introduction: In recent years, target therapies to specific molecular alterations in advanced non–small cell lung cancer (NSCLC) have been identified and have shown superior efficacy compared to non-targeted treatments. Anaplastic lymphoma kinase (ALK) is one of the therapeutic targets; nevertheles...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
AboutScience Srl
2022-09-01
|
| Series: | Global & Regional Health Technology Assessment |
| Subjects: | |
| Online Access: | https://journals.aboutscience.eu/index.php/grhta/article/view/2449 |
| _version_ | 1811209890124791808 |
|---|---|
| author | Margarita Majem Rosa Álvarez Ana Laura Ortega Lucía Ruiz de Alda Rocío Gordo J Francisco García Yoana Ivanova-Markova Almudena González-Domínguez Raquel Sánchez San Cristóbal Federico Rojo |
| author_facet | Margarita Majem Rosa Álvarez Ana Laura Ortega Lucía Ruiz de Alda Rocío Gordo J Francisco García Yoana Ivanova-Markova Almudena González-Domínguez Raquel Sánchez San Cristóbal Federico Rojo |
| author_sort | Margarita Majem |
| collection | DOAJ |
| description |
Introduction: In recent years, target therapies to specific molecular alterations in advanced non–small cell lung cancer (NSCLC) have been identified and have shown superior efficacy compared to non-targeted treatments. Anaplastic lymphoma kinase (ALK) is one of the therapeutic targets; nevertheless, ALK diagnosis is not performed in all NSCLC patients in Spain. The objective of this study is to estimate in monetary terms the benefit for the Spanish society of ALK diagnosis in advanced NSCLC patients.
Methods: A cost-benefit analysis of ALK diagnosis vs. non-diagnosis in advanced NSCLC patients was carried out from the Spanish social perspective, with a time horizon of 5 years. Costs, benefits and the cost-benefit ratio weremeasured. The analysis has considered the overall survival in advanced NSCLC patients treated with the ALKtyrosine kinase inhibitor (TKI) alectinib. The natural history of NSCLC was simulated using a Markov model. A 3% discount rate was applied to both costs and benefits. The result was tested using a deterministic sensitivity analysis.
Results: The cost of ALK diagnosis vs. non-diagnosis in the base case would be €10.19 million, generating benefits of €11.71 million. The cost-benefit ratio would be €1.15. In the sensitivity analysis, the cost-benefit ratio could range from €0.89 to €2.10.
Conclusions: The results justify the universal application of ALK diagnosis in advanced NSCLC, which generates a benefit for Spanish society that outweighs its costs and allows optimal treatment with targeted therapies for these patients.
|
| first_indexed | 2024-04-12T04:47:50Z |
| format | Article |
| id | doaj.art-402c993ed5354796aa9842c6ee13acd6 |
| institution | Directory Open Access Journal |
| issn | 2284-2403 2283-5733 |
| language | English |
| last_indexed | 2024-04-12T04:47:50Z |
| publishDate | 2022-09-01 |
| publisher | AboutScience Srl |
| record_format | Article |
| series | Global & Regional Health Technology Assessment |
| spelling | doaj.art-402c993ed5354796aa9842c6ee13acd62022-12-22T03:47:26ZengAboutScience SrlGlobal & Regional Health Technology Assessment2284-24032283-57332022-09-019110.33393/grhta.2022.2449Cost-benefit analysis of ALK diagnosis vs. non-diagnosis in patients with advanced non–small cell lung cancer in SpainMargarita Majem0Rosa Álvarez1Ana Laura Ortega2Lucía Ruiz de Alda3Rocío Gordo4J Francisco García5Yoana Ivanova-Markova6Almudena González-Domínguez7Raquel Sánchez San Cristóbal8Federico Rojo9Hospital de la Santa Creu i Sant Pau, Barcelona - SpainHospital Gregorio Marañón, Madrid - SpainHospital Universitario de Jaén, Jaén - SpainRoche Farma, Madrid - SpainRoche Farma, Madrid - SpainRoche Farma, Madrid - SpainWeber, Madrid - SpainWeber, Madrid - SpainWeber, Madrid - SpainHospital Universitario Fundación Jiménez Díaz, Madrid - Spain Introduction: In recent years, target therapies to specific molecular alterations in advanced non–small cell lung cancer (NSCLC) have been identified and have shown superior efficacy compared to non-targeted treatments. Anaplastic lymphoma kinase (ALK) is one of the therapeutic targets; nevertheless, ALK diagnosis is not performed in all NSCLC patients in Spain. The objective of this study is to estimate in monetary terms the benefit for the Spanish society of ALK diagnosis in advanced NSCLC patients. Methods: A cost-benefit analysis of ALK diagnosis vs. non-diagnosis in advanced NSCLC patients was carried out from the Spanish social perspective, with a time horizon of 5 years. Costs, benefits and the cost-benefit ratio weremeasured. The analysis has considered the overall survival in advanced NSCLC patients treated with the ALKtyrosine kinase inhibitor (TKI) alectinib. The natural history of NSCLC was simulated using a Markov model. A 3% discount rate was applied to both costs and benefits. The result was tested using a deterministic sensitivity analysis. Results: The cost of ALK diagnosis vs. non-diagnosis in the base case would be €10.19 million, generating benefits of €11.71 million. The cost-benefit ratio would be €1.15. In the sensitivity analysis, the cost-benefit ratio could range from €0.89 to €2.10. Conclusions: The results justify the universal application of ALK diagnosis in advanced NSCLC, which generates a benefit for Spanish society that outweighs its costs and allows optimal treatment with targeted therapies for these patients. https://journals.aboutscience.eu/index.php/grhta/article/view/2449ALKCost-benefitCost-effectivenessEconomic evaluationLung cancerNon–small cell lung cancer |
| spellingShingle | Margarita Majem Rosa Álvarez Ana Laura Ortega Lucía Ruiz de Alda Rocío Gordo J Francisco García Yoana Ivanova-Markova Almudena González-Domínguez Raquel Sánchez San Cristóbal Federico Rojo Cost-benefit analysis of ALK diagnosis vs. non-diagnosis in patients with advanced non–small cell lung cancer in Spain Global & Regional Health Technology Assessment ALK Cost-benefit Cost-effectiveness Economic evaluation Lung cancer Non–small cell lung cancer |
| title | Cost-benefit analysis of ALK diagnosis vs. non-diagnosis in patients with advanced non–small cell lung cancer in Spain |
| title_full | Cost-benefit analysis of ALK diagnosis vs. non-diagnosis in patients with advanced non–small cell lung cancer in Spain |
| title_fullStr | Cost-benefit analysis of ALK diagnosis vs. non-diagnosis in patients with advanced non–small cell lung cancer in Spain |
| title_full_unstemmed | Cost-benefit analysis of ALK diagnosis vs. non-diagnosis in patients with advanced non–small cell lung cancer in Spain |
| title_short | Cost-benefit analysis of ALK diagnosis vs. non-diagnosis in patients with advanced non–small cell lung cancer in Spain |
| title_sort | cost benefit analysis of alk diagnosis vs non diagnosis in patients with advanced non small cell lung cancer in spain |
| topic | ALK Cost-benefit Cost-effectiveness Economic evaluation Lung cancer Non–small cell lung cancer |
| url | https://journals.aboutscience.eu/index.php/grhta/article/view/2449 |
| work_keys_str_mv | AT margaritamajem costbenefitanalysisofalkdiagnosisvsnondiagnosisinpatientswithadvancednonsmallcelllungcancerinspain AT rosaalvarez costbenefitanalysisofalkdiagnosisvsnondiagnosisinpatientswithadvancednonsmallcelllungcancerinspain AT analauraortega costbenefitanalysisofalkdiagnosisvsnondiagnosisinpatientswithadvancednonsmallcelllungcancerinspain AT luciaruizdealda costbenefitanalysisofalkdiagnosisvsnondiagnosisinpatientswithadvancednonsmallcelllungcancerinspain AT rociogordo costbenefitanalysisofalkdiagnosisvsnondiagnosisinpatientswithadvancednonsmallcelllungcancerinspain AT jfranciscogarcia costbenefitanalysisofalkdiagnosisvsnondiagnosisinpatientswithadvancednonsmallcelllungcancerinspain AT yoanaivanovamarkova costbenefitanalysisofalkdiagnosisvsnondiagnosisinpatientswithadvancednonsmallcelllungcancerinspain AT almudenagonzalezdominguez costbenefitanalysisofalkdiagnosisvsnondiagnosisinpatientswithadvancednonsmallcelllungcancerinspain AT raquelsanchezsancristobal costbenefitanalysisofalkdiagnosisvsnondiagnosisinpatientswithadvancednonsmallcelllungcancerinspain AT federicorojo costbenefitanalysisofalkdiagnosisvsnondiagnosisinpatientswithadvancednonsmallcelllungcancerinspain |